<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
	<id root="A36E8B32-DBB8-948E-C157-462434EE4525"/>
	<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Labeling"/>
	<title mediaType="text/x-hl7-title+xml">TABLETS<br/>
		<content styleCode="bold">ALDORIL</content>
		<content styleCode="bold">
			<sup>&#174;</sup>
		</content>
		<br/>
		<content styleCode="bold">(METHYLDOPA-HYDROCHLOROTHIAZIDE)</content>
		<br/>
	</title>
	<effectiveTime value="20060303"/>
	<setId root="6FAF0958-76A3-49F1-A385-514298CB7992"/>
	<versionNumber value="2"/>
	<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>MERCK and CO., Inc.</name>
   </representedOrganization>
  </assignedEntity>
</author>
	<component>
		<structuredBody>
			<component>
				<section>
					<id root="F034DF29-8872-4810-0A31-5C8F69104520"/>
					<effectiveTime value="20060303"/>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0006-0423" codeSystem="2.16.840.1.113883.6.69"/>
								<name>ALDORIL</name>
								<formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="250">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="250"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>methyldopa</name>
										<activeMoiety>
											<activeMoiety>
												<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>methyldopa</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="15">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="15"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>methyldopa and hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium disodium edetate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium phosphate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>citric acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>colloidal silicon dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>ethylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>guar gum</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>hydroxypropyl methylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>propylene glycol</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>talc</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>titanium dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>iron oxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="0006-0423-68" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="11" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">MSD;423;ALDORIL</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="1" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE">
										<originalText>salmon</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
										<originalText>round</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0006-0456" codeSystem="2.16.840.1.113883.6.69"/>
								<name>ALDORIL</name>
								<formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="250">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="250"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>methyldopa</name>
										<activeMoiety>
											<activeMoiety>
												<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>methyldopa</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="25">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="25"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>methyldopa and hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium disodium edetate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium phosphate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>citric acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>colloidal silicon dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>ethylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>guar gum</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>hydroxypropyl methylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>propylene glycol</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>talc</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>titanium dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="0006-0456-68" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
								<asContent>
									<quantity>
										<numerator value="1000">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1000"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="0006-0456-82" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="11" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">MSD;456;ALDORIL</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="1" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
										<originalText>round</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
										<originalText>white</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0006-0694" codeSystem="2.16.840.1.113883.6.69"/>
								<name>ALDORIL</name>
								<formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="500">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="500"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>methyldopa</name>
										<activeMoiety>
											<activeMoiety>
												<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>methyldopa</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="30">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="30"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>methyldopa and hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium disodium edetate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium phosphate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>citric acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>colloidal silicon dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>ethylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>guar gum</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>hydroxypropyl methylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>propylene glycol</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>talc</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>titanium dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>iron oxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="0006-0694-68" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="18" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">MSD;694;ALDORIL</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="1" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
										<originalText>oval</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE">
										<originalText>salmon</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
					<subject>
						<manufacturedProduct>
							<manufacturedMedicine>
								<code code="0006-0935" codeSystem="2.16.840.1.113883.6.69"/>
								<name>ALDORIL</name>
								<formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="500">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="500"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>methyldopa</name>
										<activeMoiety>
											<activeMoiety>
												<code code="56LH93261Y" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>methyldopa</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<activeIngredient>
									<quantity>
										<numerator unit="mg" value="50">
											<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="50"/>
										</numerator>
										<denominator value="1">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="1"/>
										</denominator>
									</quantity>
									<activeIngredientSubstance>
										<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>hydrochlorothiazide</name>
										<activeMoiety>
											<activeMoiety>
												<code code="0J48LPH2TH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
												<name>hydrochlorothiazide</name>
											</activeMoiety>
										</activeMoiety>
									</activeIngredientSubstance>
								</activeIngredient>
								<asEntityWithGeneric>
									<genericMedicine>
										<name>methyldopa and hydrochlorothiazide</name>
									</genericMedicine>
								</asEntityWithGeneric>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium disodium edetate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>calcium phosphate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>cellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>citric acid</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>colloidal silicon dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>ethylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>guar gum</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<name>hydroxypropyl methylcellulose</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>magnesium stearate</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>propylene glycol</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>talc</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<inactiveIngredient>
									<inactiveIngredientSubstance>
										<code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS"/>
										<name>titanium dioxide</name>
									</inactiveIngredientSubstance>
								</inactiveIngredient>
								<asContent>
									<quantity>
										<numerator value="100">
											<translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET" value="100"/>
										</numerator>
										<denominator value="1">
											<translation value="1"/>
										</denominator>
									</quantity>
									<containerPackagedMedicine>
										<code code="0006-0935-68" codeSystem="2.16.840.1.113883.6.69"/>
										<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
									</containerPackagedMedicine>
								</asContent>
							</manufacturedMedicine>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value unit="mm" value="20" xsi:type="PQ"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSYMBOL" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="false" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value xsi:type="ST">MSD;935;ALDORIL</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="1" xsi:type="INT"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
										<originalText>oval</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOATING" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value value="true" xsi:type="BL"/>
								</characteristic>
							</subjectOf>
							<subjectOf>
								<characteristic classCode="OBS">
									<code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
									<value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
										<originalText>white</originalText>
									</value>
								</characteristic>
							</subjectOf>
							<consumedIn>
								<substanceAdministration>
									<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
								</substanceAdministration>
							</consumedIn>
						</manufacturedProduct>
					</subject>
				</section>
			</component>
			<component>
				<section>
					<id root="9B3DF91C-6AF8-E896-1A15-E1F162FB8A7A"/>
					<code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">
							<content ID="Boxed_Warning">WARNING</content>
						</content>
					</title>
					<text>
						<paragraph>This fixed combination drug is not indicated for initial
therapy of hypertension. Hypertension requires therapy titrated to the individual
patient. If the fixed combination represents the dosage so determined, its
use may be more convenient in patient management. The treatment of hypertension
is not static, but must be re-evaluated as conditions in each patient warrant.</paragraph>
					</text>
					<effectiveTime value="20060303"/>
				</section>
			</component>
			<component>
				<section>
					<id root="68AF21D6-5637-1D3D-8E4C-48DB9A20AD4C"/>
					<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">DESCRIPTION</content>
					</title>
					<text>
						<paragraph>ALDORIL<footnote ID="footnote1">&#160;Registered trademark
of MERCK &amp; CO., Inc. COPYRIGHT &#169; MERCK &amp; CO., Inc., 1986  All
rights reserved</footnote> (Methyldopa-Hydrochlorothiazide) combines two antihypertensives:
methyldopa and hydrochlorothiazide.</paragraph>
					</text>
					<effectiveTime value="20060303"/>
					<component>
						<section>
							<id root="E16FAE76-AF17-D843-09F0-CCF5D17E7370"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Methyldopa</content>
							</title>
							<text>
								<paragraph>Methyldopa is an antihypertensive and is the <content styleCode="italics">L</content>-isomer of alphamethyldopa. It is levo-3-(3,4-dihydroxyphenyl)-2-methylalanine.
Its empirical formula is C<sub>10</sub>H<sub>13</sub>NO<sub>4</sub>, with
a molecular weight of 211.22, and its structural formula is:</paragraph>
								<renderMultiMedia referencedObject="MM03000001"/>
								<paragraph>Methyldopa is
a white to yellowish white, odorless fine powder, and is soluble in water.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
							<component>
								<observationMedia ID="MM03000001">
									<id root="E021B6B0-A757-4A26-76B0-A93C64CFFD23"/>
									<value mediaType="image/jpeg" xsi:type="ED">
										<reference value="aldoril-figure-01.jpg"/>
									</value>
								</observationMedia>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="172132EC-C8C5-A430-D9AF-65EA3C8F761C"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Hydrochlorothiazide</content>
							</title>
							<text>
								<paragraph>Hydrochlorothiazide is a diuretic and antihypertensive. It
is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2<content styleCode="italics">H- </content>1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide.
Its empirical formula is C<sub>7</sub>H<sub>8</sub>ClN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> and
its structural formula is:</paragraph>
								<renderMultiMedia referencedObject="MM1138388911-1"/>
								<paragraph>Hydrochlorothiazide is a white, or practically
white, crystalline powder with a molecular weight of 297.74, which is slightly
soluble in water, but freely soluble in sodium hydroxide solution.</paragraph>
								<paragraph>ALDORIL
is supplied as tablets in four strengths for oral use:</paragraph>
								<paragraph>ALDORIL&#160;15,
contains 250&#160;mg of methyldopa and 15&#160;mg of hydrochlorothiazide.</paragraph>
								<paragraph>ALDORIL&#160;25,
contains 250&#160;mg of methyldopa and 25&#160;mg of hydrochlorothiazide.</paragraph>
								<paragraph>ALDORIL&#160;D30,
contains 500&#160;mg of methyldopa and 30&#160;mg of hydrochlorothiazide.</paragraph>
								<paragraph>ALDORIL&#160;D50,
contains 500&#160;mg of methyldopa and 50&#160;mg of hydrochlorothiazide.</paragraph>
								<paragraph>Each
tablet contains the following inactive ingredients: calcium disodium edetate,
calcium phosphate, cellulose, citric acid, colloidal silicon dioxide, ethylcellulose,
guar gum, hydroxypropyl methylcellulose, magnesium stearate, propylene glycol,
talc, and titanium dioxide. ALDORIL&#160;15 and ALDORIL&#160;D30 also contain
iron oxide.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
							<component>
								<observationMedia ID="MM1138388911-1">
									<id root="55E7E34C-B49D-4B76-7984-67934A650953"/>
									<value mediaType="image/jpeg" xsi:type="ED">
										<reference value="aldoril-figure-02.jpg"/>
									</value>
								</observationMedia>
							</component>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="190FC40D-95D5-01D4-30D7-2623BAFDDBCF"/>
					<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">CLINICAL PHARMACOLOGY</content>
					</title>
					<effectiveTime value="20060303"/>
					<component>
						<section>
							<id root="BA43102F-ADA0-F402-6568-9DC4EE9E8781"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Methyldopa</content>
							</title>
							<text>
								<paragraph>Methyldopa is an aromatic-amino-acid decarboxylase inhibitor
in animals and in man. Although the mechanism of action has yet to be conclusively
demonstrated, the antihypertensive effect of methyldopa probably is due to
its metabolism to alpha-methylnorepinephrine, which then lowers arterial pressure
by stimulation of central inhibitory alpha-adrenergic receptors, false neurotransmission,
and/or reduction of plasma renin activity. Methyldopa has been shown to cause
a net reduction in the tissue concentration of serotonin, dopamine, norepinephrine,
and epinephrine.</paragraph>
								<paragraph>Only methyldopa, the <content styleCode="italics">L</content>-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase
and to deplete animal tissues of norepinephrine. In man, the antihypertensive
activity appears to be due solely to the <content styleCode="italics">L</content>-isomer.
About twice the dose of the racemate (<content styleCode="italics">DL</content>-alpha-methyldopa)
is required for equal antihypertensive effect.</paragraph>
								<paragraph>Methyldopa
has no direct effect on cardiac function and usually does not reduce glomerular
filtration rate, renal blood flow, or filtration fraction. Cardiac output
usually is maintained without cardiac acceleration. In some patients the heart
rate is slowed.</paragraph>
								<paragraph>Normal or elevated plasma renin activity
may decrease in the course of methyldopa therapy.</paragraph>
								<paragraph>Methyldopa
reduces both supine and standing blood pressure. It usually produces highly
effective lowering of the supine pressure with infrequent symptomatic postural
hypotension. Exercise hypotension and diurnal blood pressure variations rarely
occur.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
					<component>
						<section>
							<id root="636EF25C-2630-B93B-3A3C-1B2F6F525A5D"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Hydrochlorothiazide</content>
							</title>
							<text>
								<paragraph>The mechanism of the antihypertensive effect of thiazides
is unknown. Hydrochlorothiazide does not usually affect normal blood pressure.</paragraph>
								<paragraph>Hydrochlorothiazide
affects the distal renal tubular mechanism of electrolyte reabsorption. At
maximal therapeutic dosage all thiazides are approximately equal in their
diuretic efficacy.</paragraph>
								<paragraph>Hydrochlorothiazide increases excretion
of sodium and chloride in approximately equivalent amounts. Natriuresis may
be accompanied by some loss of potassium and bicarbonate.</paragraph>
								<paragraph>After
oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts
about 6 to 12 hours.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
					<component>
						<section>
							<id root="403ED8B2-433E-5F43-88A4-315A69812F97"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Pharmacokinetics and Metabolism</content>
							</title>
							<effectiveTime value="20060303"/>
							<component>
								<section>
									<id root="3EB92DE6-717B-2668-E974-EFC45B61262F"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Methyldopa</content>
									</title>
									<text>
										<paragraph>The maximum decrease in blood pressure occurs four to six
hours after oral dosage. Once an effective dosage level is attained, a smooth
blood pressure response occurs in most patients in 12 to 24 hours. After withdrawal,
blood pressure usually returns to pretreatment levels within 24-48 hours.</paragraph>
										<paragraph>Methyldopa
is extensively metabolized. The known urinary metabolites are: &#945;-methyldopa
mono-0-sulfate; 3-0-methyl-&#945;-methyldopa; 3,4-dihydroxyphenylacetone;&#945;-methyldopamine; 3-0-methyl-&#945;-methyldopamine and their conjugates.</paragraph>
										<paragraph>Approximately
70 percent of the drug which is absorbed is excreted in the urine as methyldopa
and its mono-0-sulfate conjugate. The renal clearance is about 130&#160;mL/min
in normal subjects and is diminished in renal insufficiency. The plasma half-life
of methyldopa is 105 minutes. After oral doses, excretion is essentially complete
in 36 hours.</paragraph>
										<paragraph>Methyldopa crosses the placental barrier,
appears in cord blood, and appears in breast milk.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
							<component>
								<section>
									<id root="BA035774-B6F0-97EE-23F0-C91FD7C79A0F"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Hydrochlorothiazide</content>
									</title>
									<text>
										<paragraph>Hydrochlorothiazide is not metabolized but is eliminated
rapidly by the kidney. When plasma levels have been followed for at least
24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8
hours. At least 61 percent of the oral dose is eliminated unchanged within
24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain
barrier and is excreted in breast milk.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="D450654C-D58C-FC2F-0BE3-8628F4972BAF"/>
					<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS AND USAGE SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">INDICATION AND USAGE</content>
					</title>
					<text>
						<paragraph>Hypertension (<linkHtml href="#Boxed_Warning">see box warning</linkHtml>).</paragraph>
					</text>
					<effectiveTime value="20060303"/>
				</section>
			</component>
			<component>
				<section>
					<id root="19079D4E-112A-F16F-BC29-920D6FCDF07E"/>
					<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">CONTRAINDICATIONS</content>
					</title>
					<text>
						<paragraph ID="_CONTRAINDICATIONS"/>
						<paragraph>ALDORIL is
contraindicated in patients:</paragraph>
						<list>
							<item>with active hepatic disease, such as acute hepatitis and active cirrhosis</item>
							<item>with liver disorders previously associated with methyldopa therapy (see <linkHtml href="#_WARNINGS">WARNINGS</linkHtml>)</item>
							<item>with anuria</item>
							<item>with hypersensitivity to methyldopa, or to hydrochlorothiazide or other
sulfonamide-derived drugs</item>
							<item>on therapy with monoamine oxidase (MAO) inhibitors.</item>
						</list>
					</text>
					<effectiveTime value="20060303"/>
				</section>
			</component>
			<component>
				<section>
					<id root="734BE252-8E8B-B792-E21D-1839C7F9D4E8"/>
					<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">WARNINGS</content>
					</title>
					<text>
						<paragraph ID="_WARNINGS"/>
					</text>
					<effectiveTime value="20060303"/>
					<component>
						<section>
							<id root="1A7715FA-DE93-8188-A30E-1F6899623FFD"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Methyldopa</content>
							</title>
							<text>
								<paragraph>
									<content styleCode="bold">It is important to recognize that
a positive Coombs test, hemolytic anemia, and liver disorders may occur with
methyldopa therapy. The rare occurrences of hemolytic anemia or liver disorders
could lead to potentially fatal complications unless properly recognized and
managed. Read this section carefully to understand these reactions.</content>
								</paragraph>
								<paragraph>With
prolonged methyldopa therapy, 10 to 20 percent of patients develop a positive
direct Coombs test which usually occurs between 6 and 12 months of methyldopa
therapy. Lowest incidence is at daily dosage of 1&#160;g or less. This on
rare occasions may be associated with hemolytic anemia, which could lead to
potentially fatal complications. One cannot predict which patients with a
positive direct Coombs test may develop hemolytic anemia.</paragraph>
								<paragraph>Prior
existence or development of a positive direct Coombs test is not in itself
a contraindication to use of methyldopa. If a positive Coombs test develops
during methyldopa therapy, the physician should determine whether hemolytic
anemia exists and whether the positive Coombs test may be a problem. For example,
in addition to a positive direct Coombs test there is less often a positive
indirect Coombs test which may interfere with cross matching of blood.</paragraph>
								<paragraph>Before
treatment is started it is desirable to do a blood count (hematocrit, hemoglobin,
or red cell count) for a baseline or to establish whether there is anemia.
Periodic blood counts should be done during therapy to detect hemolytic anemia.
It may be useful to do a direct Coombs test before therapy and at 6 and 12
months after the start of therapy.</paragraph>
								<paragraph>If Coombs-positive
hemolytic anemia occurs, the cause may be methyldopa and the drug should be
discontinued. Usually the anemia remits promptly. If not, corticosteroids
may be given and other causes of anemia should be considered. If the hemolytic
anemia is related to methyldopa, the drug should not be reinstituted.</paragraph>
								<paragraph>When
methyldopa causes Coombs positivity alone or with hemolytic anemia, the red
cell is usually coated with gamma globulin of the IgG (gamma&#160;G) class
only. The positive Coombs test may not revert to normal until weeks to months
after methyldopa is stopped.</paragraph>
								<paragraph>Should the need for transfusion
arise in a patient receiving methyldopa, both a direct and an indirect Coombs
test should be performed. In the absence of hemolytic anemia, usually only
the direct Coombs test will be positive. A positive direct Coombs test alone
will not interfere with typing or cross matching. If the indirect Coombs test
is also positive, problems may arise in the major cross match and the assistance
of a hematologist or transfusion expert will be needed.</paragraph>
								<paragraph>Occasionally,
fever has occurred within the first three weeks of methyldopa therapy, associated
in some cases with eosinophilia or abnormalities in one or more liver function
tests, such as serum alkaline phosphatase, serum transaminases (SGOT, SGPT),
bilirubin, and prothrombin time. Jaundice, with or without fever, may occur
with onset usually within the first two to three months of therapy. In some
patients the findings are consistent with those of cholestasis. In others
the findings are consistent with hepatitis and hepatocellular injury.</paragraph>
								<paragraph>Rarely,
fatal hepatic necrosis has been reported after use of methyldopa. These hepatic
changes may represent hypersensitivity reactions. Periodic determination of
hepatic function should be done particularly during the first 6 to 12 weeks
of therapy or whenever an unexplained fever occurs. If fever, abnormalities
in liver function tests, or jaundice appear, stop therapy with methyldopa.
If caused by methyldopa, the temperature and abnormalities in liver function
characteristically have reverted to normal when the drug was discontinued.
Methyldopa should not be reinstituted in such patients.</paragraph>
								<paragraph>Rarely,
a reversible reduction of the white blood cell count with a primary effect
on the granulocytes has been seen. The granulocyte count returned promptly
to normal on discontinuance of the drug. Rare cases of granulocytopenia have
been reported. In each instance, upon stopping the drug, the white cell count
returned to normal. Reversible thrombocytopenia has occurred rarely.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
					<component>
						<section>
							<id root="86A29D0B-DFCD-7964-E5F3-0BA9F5E51C16"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Hydrochlorothiazide</content>
							</title>
							<text>
								<paragraph>Use with caution in severe renal disease. In patients with
renal disease, thiazides may precipitate azotemia. Cumulative effects of the
drug may develop in patients with impaired renal function.</paragraph>
								<paragraph>Thiazides
should be used with caution in patients with impaired hepatic function or
progressive liver disease, since minor alterations of fluid and electrolyte
balance may precipitate hepatic coma.</paragraph>
								<paragraph>Thiazides may
add to or potentiate the action of other antihypertensive drugs.</paragraph>
								<paragraph>Sensitivity
reactions may occur in patients with or without a history of allergy or bronchial
asthma.</paragraph>
								<paragraph>The possibility of exacerbation or activation
of systemic lupus erythematosus has been reported.</paragraph>
								<paragraph>Lithium
generally should not be given with diuretics (see <linkHtml href="#_Drug_Interactions">PRECAUTIONS,
Drug Interactions</linkHtml>).</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="D6B1B469-75E1-F39D-89BD-61FDCD6326F3"/>
					<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">PRECAUTIONS</content>
					</title>
					<text>
						<paragraph ID="_PRECAUTIONS"/>
					</text>
					<effectiveTime value="20060303"/>
					<component>
						<section>
							<id root="E0A49F3F-408F-A08A-57CD-B8C38BB4D61F"/>
							<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">General</content>
							</title>
							<text>
								<paragraph ID="_General"/>
							</text>
							<effectiveTime value="20060303"/>
							<component>
								<section>
									<id root="2613F7A8-712F-E749-80E0-D7A4FCCFA552"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Methyldopa</content>
									</title>
									<text>
										<paragraph>Methyldopa should be used with caution in patients with a
history of previous liver disease or dysfunction (see <linkHtml href="#_WARNINGS">WARNINGS</linkHtml>).</paragraph>
										<paragraph>Some
patients taking methyldopa experience clinical edema or weight gain which
may be controlled by use of a diuretic. Methyldopa should not be continued
if edema progresses or signs of heart failure appear.</paragraph>
										<paragraph>Hypertension
has recurred occasionally after dialysis in patients given methyldopa because
the drug is removed by this procedure.</paragraph>
										<paragraph>Rarely, involuntary
choreoathetotic movements have been observed during therapy with methyldopa
in patients with severe bilateral cerebrovascular disease. Should these movements
occur, stop therapy.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
							<component>
								<section>
									<id root="DD2BB56A-5017-9249-152B-DFB176B708C1"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Hydrochlorothiazide</content>
									</title>
									<text>
										<paragraph>All patients receiving diuretic therapy should be observed
for evidence of fluid or electrolyte imbalance: namely; hyponatremia, hypochloremic
alkalosis, and hypokalemia. Serum and urine electrolyte determinations are
particularly important when the patient is vomiting excessively or receiving
parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance,
irrespective of cause, include dryness of mouth, thirst, weakness, lethargy,
drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular
fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances
such as nausea and vomiting.</paragraph>
										<paragraph>Hypokalemia may develop,
especially after prolonged therapy or when severe cirrhosis is present (see <linkHtml href="#_CONTRAINDICATIONS">CONTRAINDICATIONS</linkHtml> and <linkHtml href="#_WARNINGS">WARNINGS</linkHtml>).</paragraph>
										<paragraph>Interference
with adequate oral electrolyte intake will also contribute to hypokalemia.
Hypokalemia may cause cardiac arrhythmia and may also sensitize or exaggerate
the response of the heart to the toxic effects of digitalis (e.g., increased
ventricular irritability). Hypokalemia may be avoided or treated by use of
potassium sparing diuretics or potassium supplements such as foods with a
high potassium content.</paragraph>
										<paragraph>Although any chloride deficit
is generally mild and usually does not require specific treatment except under
extraordinary circumstances (as in liver disease or renal disease), chloride
replacement may be required in the treatment of metabolic alkalosis.</paragraph>
										<paragraph>Dilutional
hyponatremia may occur in edematous patients in hot weather; appropriate therapy
is water restriction, rather than administration of salt, except in rare instances
when the hyponatremia is life-threatening. In actual salt depletion appropriate
replacement is the therapy of choice.</paragraph>
										<paragraph>Hyperuricemia
may occur or acute gout may be precipitated in certain patients receiving
thiazides.</paragraph>
										<paragraph>In diabetic patients dosage adjustment of
insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur
with thiazide diuretics. Thus latent diabetes mellitus may become manifest
during thiazide therapy.</paragraph>
										<paragraph>The antihypertensive effects
of the drug may be enhanced in the postsympathectomy patient.</paragraph>
										<paragraph>If
progressive renal impairment becomes evident, consider withholding or discontinuing
diuretic therapy.</paragraph>
										<paragraph>Thiazides have been shown to increase
the urinary excretion of magnesium; this may result in hypomagnesemia.</paragraph>
										<paragraph>Thiazides
may decrease urinary calcium excretion. Thiazides may cause intermittent and
slight elevation of serum calcium in the absence of known disorders of calcium
metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism.
Thiazides should be discontinued before carrying out tests for parathyroid
function.</paragraph>
										<paragraph>Increases in cholesterol and triglyceride
levels may be associated with thiazide diuretic therapy.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="A2971FFF-FD1C-9069-0967-7EE41AB75A77"/>
							<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Laboratory Tests</content>
							</title>
							<effectiveTime value="20060303"/>
							<component>
								<section>
									<id root="1C9E026C-1940-02A9-0AF4-F2982591BAE9"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Methyldopa</content>
									</title>
									<text>
										<paragraph>Blood count, Coombs test and liver function test, are recommended
before initiating therapy and at periodic intervals (see <linkHtml href="#_WARNINGS">WARNINGS</linkHtml>).</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
							<component>
								<section>
									<id root="1DE84300-D4E9-02BD-C8A9-E9901635FFB6"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Hydrochlorothiazide</content>
									</title>
									<text>
										<paragraph>Periodic determination of serum electrolytes to detect possible
electrolyte imbalance should be done at appropriate intervals.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="9A8F7042-4BF9-20B7-AAF0-9CF8B5F821A5"/>
							<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Drug Interactions</content>
							</title>
							<text>
								<paragraph ID="_Drug_Interactions"/>
							</text>
							<effectiveTime value="20060303"/>
							<component>
								<section>
									<id root="0E49437A-17C4-7105-8738-AA9E5BCAE2EE"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Methyldopa</content>
									</title>
									<text>
										<paragraph>When methyldopa is used with other antihypertensive drugs,
potentiation of antihypertensive effect may occur. Patients should be followed
carefully to detect side reactions or unusual manifestations of drug idiosyncrasy.</paragraph>
										<paragraph>Patients
may require reduced doses of anesthetics when on methyldopa. If hypotension
does occur during anesthesia, it usually can be controlled by vasopressors.
The adrenergic receptors remain sensitive during treatment with methyldopa.</paragraph>
										<paragraph>When
methyldopa and lithium are given concomitantly the patient should be carefully
monitored for symptoms of lithium toxicity. Read the prescribing information
for lithium preparations.</paragraph>
										<paragraph>Several studies demonstrate
a decrease in the bioavailability of methyldopa when it is ingested with ferrous
sulfate or ferrous gluconate. This may adversely affect blood pressure control
in patients treated with methyldopa. Coadministration of methyldopa with ferrous
sulfate or ferrous gluconate is not recommended.</paragraph>
										<paragraph>Monoamine
oxidase (MAO) inhibitors: See <linkHtml href="#_CONTRAINDICATIONS">CONTRAINDICATIONS</linkHtml>.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
							<component>
								<section>
									<id root="920F7617-9CD3-B1A7-047B-08422CD5A464"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Hydrochlorothiazide</content>
									</title>
									<text>
										<paragraph>When given concurrently the following drugs may interact
with thiazide diuretics.</paragraph>
										<paragraph>
											<content styleCode="italics">Alcohol,
barbiturates, or narcotics</content>&#160;&#8212; potentiation of orthostatic
hypotension may occur.</paragraph>
										<paragraph>
											<content styleCode="italics">Antidiabetic
drugs </content>(oral agents and insulin)&#160;&#8212; dosage adjustment
of the antidiabetic drug may be required.</paragraph>
										<paragraph>
											<content styleCode="italics">Other
antihypertensive drugs</content>&#160;&#8212; additive effect or potentiation.</paragraph>
										<paragraph>
											<content styleCode="italics">Cholestyramine and colestipol resins</content>&#160;&#8212;
Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange
resins. Single doses of either cholestyramine or colestipol resins bind the
hydrochlorothiazide and reduce its absorption from the gastrointestinal tract
by up to 85 and 43 percent, respectively.</paragraph>
										<paragraph>
											<content styleCode="italics">Corticosteroids,
ACTH</content>&#160;&#8212; intensified electrolyte depletion, particularly
hypokalemia.</paragraph>
										<paragraph>
											<content styleCode="italics">Pressor amines
(e.g., norepinephrine)</content>&#160;&#8212; possible decreased response
to pressor amines but not sufficient to preclude their use.</paragraph>
										<paragraph>
											<content styleCode="italics">Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)</content>&#160;&#8212; possible increased responsiveness to the muscle
relaxant.</paragraph>
										<paragraph>
											<content styleCode="italics">Lithium</content>&#160;&#8212;
generally should not be given with diuretics. Diuretic agents reduce the renal
clearance of lithium and add a high risk of lithium toxicity. Refer to the
package insert for lithium preparations before use of such preparations with
ALDORIL.</paragraph>
										<paragraph>
											<content styleCode="italics">Non-steroidal
Anti-inflammatory Drugs</content>&#160;&#8212; In some patients, the administration
of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic,
and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
Therefore, when ALDORIL and non-steroidal anti-inflammatory agents are used
concomitantly, the patient should be observed closely to determine if the
desired effect of the diuretic is obtained.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="27B95DA3-B5C5-57B9-65E9-24E4F879DB70"/>
							<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG AND OR LABORATORY TEST INTERACTIONS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Drug/Laboratory Test Interactions</content>
							</title>
							<effectiveTime value="20060303"/>
							<component>
								<section>
									<id root="F4759FE2-8F9E-509B-F71C-B2474FD5BB87"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Methyldopa</content>
									</title>
									<text>
										<paragraph>Methyldopa may interfere with measurement of: urinary uric
acid by the phosphotungstate method, serum creatinine by the alkaline picrate
method, and SGOT by colorimetric methods. Interference with spectrophotometric
methods for SGOT analysis has not been reported.</paragraph>
										<paragraph>Since
methyldopa causes fluorescence in urine samples at the same wave lengths as
catecholamines, falsely high levels of urinary catecholamines may be reported.
This will interfere with the diagnosis of pheochromocytoma. It is important
to recognize this phenomenon before a patient with a possible pheochromocytoma
is subjected to surgery. Methyldopa does not interfere with measurement of
VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods
which convert VMA to vanillin. Methyldopa is not recommended for the treatment
of patients with pheochromocytoma. Rarely, when urine is exposed to air after
voiding, it may darken because of breakdown of methyldopa or its metabolites.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
							<component>
								<section>
									<id root="F45A0690-7710-B7F6-96F0-C45F83447E6A"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Hydrochlorothiazide</content>
									</title>
									<text>
										<paragraph>Thiazides should be discontinued before carrying out tests
for parathyroid function (see <linkHtml href="#_General">PRECAUTIONS, General</linkHtml>).</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="2F57FF10-9576-DACF-9A71-4E08AA8D78B2"/>
							<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Carcinogenesis,&#160;Mutagenesis, Impairment&#160;of&#160;Fertility</content>
							</title>
							<text>
								<paragraph>Long-term studies in animals have not been performed to evaluate
the effects upon fertility, mutagenic or carcinogenic potential of the combination.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
							<component>
								<section>
									<id root="A816E90A-11C5-D6CE-4E32-9DBB59A1C1C1"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Methyldopa</content>
									</title>
									<text>
										<paragraph>No evidence of a tumorigenic effect was seen when methyldopa
was given for two years to mice at doses up to 1800 mg/kg/day or to rats at
doses up to 240 mg/kg/day (30 and 4 times the maximum recommended human dose
in mice and rats, respectively, when compared on the basis of body weight;
2.5 and 0.6 times the maximum recommended human dose in mice and rats, respectively,
when compared on the basis of body surface area; calculations assume a patient
weight of 50&#160;kg).</paragraph>
										<paragraph>Methyldopa was not mutagenic
in the Ames Test and did not increase chromosomal aberration or sister chromatid
exchanges in Chinese hamster ovary cells. These <content styleCode="italics">in
vitro </content> studies were carried out both with and without exogenous
metabolic activation.</paragraph>
										<paragraph>Fertility was unaffected when
methyldopa was given to male and female rats at 100 mg/kg/day (1.7 times the
maximum daily human dose when compared on the basis of body weight; 0.2 times
the maximum daily human dose when compared on the basis of body surface area).
Methyldopa decreased sperm count, sperm motility, the number of late spermatids
and the male fertility index when given to male rats at 200 and 400 mg/kg/day
(3.3 and 6.7 times the maximum daily human dose when compared on the basis
of body weight; 0.5 and 1 times the maximum daily human dose when compared
on the basis of body surface area).</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
							<component>
								<section>
									<id root="3F85BF43-BFBC-BDF8-6B17-40758A7C07DD"/>
									<title mediaType="text/x-hl7-title+xml">
										<content styleCode="italics">Hydrochlorothiazide</content>
									</title>
									<text>
										<paragraph>Two-year feeding studies in mice and rats conducted under
the auspices of the National Toxicology Program (NTP) uncovered no evidence
of a carcinogenic potential of hydrochlorothiazide in female mice (at doses
of up to approximately 600 mg/kg/day) or in male and female rats (at doses
of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence
for hepatocarcinogenicity in male mice.</paragraph>
										<paragraph>Hydrochlorothiazide
was not genotoxic <content styleCode="italics">in vitro</content> in the Ames
mutagenicity assay of <content styleCode="italics">Salmonella typhimurium</content> strains TA&#160;98, TA&#160;100, TA&#160;1535, TA&#160;1537, and
TA&#160;1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations,
or <content styleCode="italics">in vivo</content> in assays using mouse germinal
cell chromosomes, Chinese hamster bone marrow chromosomes, and the <content styleCode="italics">Drosophila</content> sex-linked recessive lethal trait
gene. Positive test results were obtained only in the <content styleCode="italics">in
vitro</content> CHO Sister Chromatid Exchange (clastogenicity) and in the
Mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide
from 43 to 1300&#160;&#181;g/mL, and in the <content styleCode="italics">Aspergillus
nidulans</content> non-disjunction assay at an unspecified concentration.</paragraph>
										<paragraph>Hydrochlorothiazide
had no adverse effects on the fertility of mice and rats of either sex in
studies wherein these species were exposed, via their diet, to doses of up
to 100 and 4&#160;mg/kg, respectively, prior to conception and throughout
gestation.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="180D12D9-FFD8-8FC3-EA7F-AA49BAACFE0F"/>
							<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Pregnancy</content>
							</title>
							<text>
								<paragraph>Use of diuretics during normal pregnancy is inappropriate
and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent
development of toxemia of pregnancy and there is no satisfactory evidence
that they are useful in the treatment of toxemia.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
							<component>
								<section>
									<id root="35464AFC-7006-BE63-9546-136B31C70BD0"/>
									<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Teratogenic Effects section"/>
									<title mediaType="text/x-hl7-title+xml">Teratogenic Effects</title>
									<text>
										<paragraph>
											<content styleCode="italics">Pregnancy Category&#160;C: </content> Animal reproduction studies have not been conducted with ALDORIL.
It is also not known whether ALDORIL can affect reproduction capacity or can
cause fetal harm when given to a pregnant woman. ALDORIL should be given to
a pregnant woman only if clearly needed.</paragraph>
										<paragraph>
											<content styleCode="italics">Hydrochlorothiazide:</content> Studies in which hydrochlorothiazide was orally administered to
pregnant mice and rats during their respective periods of major organogenesis
at doses up to 3000 and 1000&#160;mg hydrochlorothiazide/kg, respectively,
provided no evidence of harm to the fetus. There are, however, no adequate
and well-controlled studies in pregnant women.</paragraph>
										<paragraph>
											<content styleCode="italics">Methyldopa: </content> Reproduction studies performed
with methyldopa at oral doses up to 1000&#160;mg/kg in mice, 200&#160;mg/kg
in rabbits and 100&#160;mg/kg in rats revealed no evidence of harm to the
fetus. These doses are 16.6 times, 3.3 times and 1.7 times, respectively,
the maximum daily human dose when compared on the basis of body weight; 1.4
times, 1.1 times and 0.2 times, respectively, when compared on the basis of
body surface area; calculations assume a patient weight of 50&#160;kg. There
are, however, no adequate and well-controlled studies in pregnant women in
the first trimester of pregnancy. Because animal reproduction studies are
not always predictive of human response, methyldopa should be used during
pregnancy only if clearly needed.</paragraph>
										<paragraph>Published reports
of the use of methyldopa during all trimesters indicate that if this drug
is used during pregnancy the possibility of fetal harm appears remote. In
five studies, three of which were controlled, involving 332 pregnant hypertensive
women, treatment with methyldopa was associated with an improved fetal outcome.
The majority of these women were in the third trimester when methyldopa therapy
was begun.</paragraph>
										<paragraph>In one study, women who had begun methyldopa
treatment between weeks 16 and 20 of pregnancy gave birth to infants whose
average head circumference was reduced by a small amount (34.2&#160;&#177;&#160;1.7
cm vs. 34.6&#160;&#177;&#160;1.3 cm [mean&#160;&#177;&#160;1 S.D.]). Long
term follow-up of 195 (97.5%) of the children born to methyldopa-treated pregnant
women (including those who began treatment between weeks 16 and 20) failed
to uncover any significant adverse effect on the children. At four years of
age, the developmental delay commonly seen in children born to hypertensive
mothers was less evident in those whose mothers were treated with methyldopa
during pregnancy than those whose mothers were untreated. The children of
the treated group scored consistently higher than the children of the untreated
group on five major indices of intellectual and motor development. At age
7 and one-half developmental scores and intelligence indices showed no significant
differences in children of treated or untreated hypertensive women.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
							<component>
								<section>
									<id root="4114953E-4BE3-192E-A10C-F4A060C96599"/>
									<code code="34078-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nonteratogenic Effects section"/>
									<title mediaType="text/x-hl7-title+xml">Nonteratogenic Effects</title>
									<text>
										<paragraph>Thiazides cross the placental barrier and appear in cord
blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and
possibly other adverse reactions that have occurred in adults.</paragraph>
									</text>
									<effectiveTime value="20060303"/>
								</section>
							</component>
						</section>
					</component>
					<component>
						<section>
							<id root="C3DAA108-875E-2981-6B0A-DC28E7EF8123"/>
							<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Nursing Mothers</content>
							</title>
							<text>
								<paragraph>Methyldopa and thiazides appear in breast milk. Therefore,
because of the potential for serious adverse reactions in nursing infants
from hydrochlorothiazide, a decision should be made whether to discontinue
nursing or to discontinue the drug, taking into account the importance of
the drug to the mother.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
					<component>
						<section>
							<id root="77D6C393-6949-F368-CB74-0C846F27B60C"/>
							<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Geriatric Use section"/>
							<title mediaType="text/x-hl7-title+xml">
								<content ID="PRECAUTIONS_Geriatric_Use">
									<content styleCode="italics">Geriatric
Use</content>
								</content>
							</title>
							<text>
								<paragraph>Clinical studies of ALDORIL did not include sufficient numbers
of subjects aged 65 and over to determine whether they respond differently
from younger subjects.  Other reported clinical experience has not identified
differences in responses between the elderly and younger patients.  In general,
dose selection for an elderly patient should be cautious, usually starting
at the low end of the dosing range, reflecting the greater frequency of decreased
hepatic, renal, or cardiac function, and of concomitant disease or other drug
therapy. </paragraph>
								<paragraph>This drug is known to be substantially excreted
by the kidney, and the risk of toxic reactions to this drug may be greater
in patients with impaired renal function.  Because elderly patients are more
likely to have decreased renal function, care should be taken in dose selection,
and it may be useful to monitor renal function.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
					<component>
						<section>
							<id root="B05CED4F-819A-256F-DBC7-294BED5708E8"/>
							<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Pediatric Use</content>
							</title>
							<text>
								<paragraph>Safety and effectiveness of ALDORIL in pediatric patients
have not been established.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="E3EC6C5D-F699-0555-E0AB-793D8C8BF303"/>
					<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">ADVERSE REACTIONS</content>
					</title>
					<text>
						<paragraph>The following adverse reactions have been reported and, within
each category, are listed in order of decreasing severity.</paragraph>
					</text>
					<effectiveTime value="20060303"/>
					<component>
						<section>
							<id root="1FB2AB47-585F-CB1C-4071-B2E11877542B"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Methyldopa</content>
							</title>
							<text>
								<paragraph>Sedation, usually transient, may occur during the initial
period of therapy or whenever the dose is increased. Headache, asthenia, or
weakness may be noted as early and transient symptoms. However, significant
adverse effects due to methyldopa have been infrequent and this agent usually
is well tolerated.</paragraph>
								<paragraph>
									<content styleCode="italics">Cardiovascular:</content> Aggravation of angina pectoris, congestive heart failure, prolonged
carotid sinus hypersensitivity, orthostatic hypotension (decrease daily dosage),
edema or weight gain, bradycardia.</paragraph>
								<paragraph>
									<content styleCode="italics">Digestive:</content> Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore
or &#8220;black&#8221; tongue, nausea, constipation, distention, flatus,
dryness of mouth.</paragraph>
								<paragraph>
									<content styleCode="italics">Endocrine:</content> Hyperprolactinemia.</paragraph>
								<paragraph>
									<content styleCode="italics">Hematologic:</content> Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia,
hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid
factor, positive Coombs test.</paragraph>
								<paragraph>
									<content styleCode="italics">Hepatic:</content> Liver disorders including hepatitis, jaundice, abnormal liver
function tests (see <linkHtml href="#_WARNINGS">WARNINGS</linkHtml>).</paragraph>
								<paragraph>
									<content styleCode="italics">Hypersensitivity: </content> Myocarditis, pericarditis,
vasculitis, lupus-like syndrome, drug-related fever, eosinophilia.</paragraph>
								<paragraph>
									<content styleCode="italics">Nervous System/Psychiatric:</content> Parkinsonism, Bell's
palsy, decreased mental acuity, involuntary choreoathetotic movements, symptoms
of cerebrovascular insufficiency, psychic disturbances including nightmares
and reversible mild psychoses or depression, headache, sedation, asthenia
or weakness, dizziness, lightheadedness, paresthesias.</paragraph>
								<paragraph>
									<content styleCode="italics">Metabolic:</content> Rise in BUN.</paragraph>
								<paragraph>
									<content styleCode="italics">Musculoskeletal:</content> Arthralgia, with or without
joint swelling; myalgia.</paragraph>
								<paragraph>
									<content styleCode="italics">Respiratory:</content> Nasal stuffiness.</paragraph>
								<paragraph>
									<content styleCode="italics">Skin:</content> Toxic epidermal necrolysis, rash.</paragraph>
								<paragraph>
									<content styleCode="italics">Urogenital:</content> Amenorrhea, breast enlargement,
gynecomastia, lactation, impotence, decreased libido.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
					<component>
						<section>
							<id root="2F05ADF1-922C-35E1-F03B-3C9EC7E5520F"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Hydrochlorothiazide</content>
							</title>
							<text>
								<paragraph>
									<content styleCode="italics">Body as a Whole:</content> Weakness.</paragraph>
								<paragraph>
									<content styleCode="italics">Cardiovascular:</content> Hypotension including orthostatic
hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive
drugs).</paragraph>
								<paragraph>
									<content styleCode="italics">Digestive:</content> Pancreatitis,
jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis,
cramping, constipation, gastric irritation, nausea, anorexia.</paragraph>
								<paragraph>
									<content styleCode="italics">Hematologic: </content> Aplastic anemia, agranulocytosis,
leukopenia, hemolytic anemia, thrombocytopenia.</paragraph>
								<paragraph>
									<content styleCode="italics">Hypersensitivity:</content> Anaphylactic reactions, necrotizing
angiitis (vasculitis and cutaneous vasculitis), respiratory distress including
pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash,
purpura.</paragraph>
								<paragraph>
									<content styleCode="italics">Metabolic: </content>Electrolyte
imbalance (see <linkHtml href="#_PRECAUTIONS">PRECAUTIONS</linkHtml>), hyperglycemia,
glycosuria, hyperuricemia.</paragraph>
								<paragraph>
									<content styleCode="italics">Musculoskeletal:</content> Muscle spasm.</paragraph>
								<paragraph>
									<content styleCode="italics">Nervous
System/Psychiatric:</content> Vertigo, paresthesias, dizziness, headache,
restlessness.</paragraph>
								<paragraph>
									<content styleCode="italics">Renal:</content> Renal
failure, renal dysfunction, interstitial nephritis. (See <linkHtml href="#_WARNINGS">WARNINGS</linkHtml>.)</paragraph>
								<paragraph>
									<content styleCode="italics">Skin:</content> Erythema multiforme including Stevens-Johnson
syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia.</paragraph>
								<paragraph>
									<content styleCode="italics">Special Senses:</content> Transient blurred vision, xanthopsia.</paragraph>
								<paragraph>
									<content styleCode="italics">Urogenital:</content> Impotence.</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
				</section>
			</component>
			<component>
				<section>
					<id root="E905CE66-0C1F-63AB-FA12-A777CA079BE5"/>
					<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">OVERDOSAGE</content>
					</title>
					<text>
						<paragraph>Acute overdosage may produce acute hypotension with other
responses attributable to brain and gastrointestinal malfunction (excessive
sedation, weakness, bradycardia, dizziness, lightheadedness, constipation,
distention, flatus, diarrhea, nausea, vomiting).</paragraph>
						<paragraph>In
the event of overdosage, symptomatic and supportive measures should be employed.
When ingestion is recent, gastric lavage or emesis may reduce absorption.
When ingestion has been earlier, infusions may be helpful to promote urinary
excretion. Otherwise, management includes special attention to cardiac rate
and output, blood volume, electrolyte balance, paralytic ileus, urinary function
and cerebral activity.</paragraph>
						<paragraph>Sympathomimetic drugs [e.g.,
levarterenol, epinephrine, ARAMINE<footnoteRef IDREF="footnote1"/> (Metaraminol
Bitartrate)] may be indicated. Methyldopa is dialyzable. The degree to which
hydrochlorothiazide is removed by hemodialysis has not been established.</paragraph>
						<paragraph>The
oral LD<sub>50</sub> of methyldopa is greater than 1.5&#160;g/kg in both the
mouse and the rat. The oral LD<sub>50</sub> of hydrochlorothiazide is greater
than 10&#160;g/kg in the mouse and rat.</paragraph>
					</text>
					<effectiveTime value="20060303"/>
				</section>
			</component>
			<component>
				<section>
					<id root="C7B2DD39-C45F-BC41-603D-D8932C03CF71"/>
					<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE AND ADMINISTRATION SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
					</title>
					<text>
						<paragraph ID="SECTNBEG"/>
						<paragraph>DOSAGE MUST BE INDIVIDUALIZED,
AS DETERMINED BY TITRATION OF THE INDIVIDUAL COMPONENTS (<linkHtml href="#Boxed_Warning">see
box warning</linkHtml>). Once the patient has been successfully titrated,
ALDORIL may be substituted if the previously determined titrated doses are
the same as in the combination. The usual starting dosage is one tablet of
ALDORIL&#160;15 two or three times a day or one tablet of ALDORIL&#160;25
two times a day. Alternatively, one tablet of ALDORIL&#160;D30 or ALDORIL&#160;D50
once daily may be used. Hydrochlorothiazide doses greater than 50 mg daily
should be avoided.</paragraph>
						<paragraph>Hydrochlorothiazide can be given
at doses of 12.5 to 50 mg per day when used alone. The usual daily dosage
of methyldopa is 500&#160;mg to 2&#160;g. To minimize the sedation associated
with methyldopa, start dosage increases in the evening. The maximum recommended
daily dose of methyldopa is 3 g.</paragraph>
						<paragraph>Occasionally tolerance
to methyldopa may occur, usually between the second and third month of therapy.
Additional separate doses of methyldopa or replacement of ALDORIL with single
entity agents is necessary until the new effective dose ratio is re-established
by titration. If ALDORIL does not adequately control blood pressure, additional
doses of other agents may be given. When ALDORIL is given with antihypertensives
other than thiazides, the initial dosage of methyldopa should be limited to
500&#160;mg daily in divided doses and the dose of these other agents may
need to be adjusted to effect a smooth transition.</paragraph>
						<paragraph>Since
both components of ALDORIL have a relatively short duration of action, withdrawal
is followed by return of hypertension usually within 48 hours. This is not
complicated by an overshoot of blood pressure.</paragraph>
						<paragraph>Since
methyldopa is largely excreted by the kidney, patients with impaired renal
function may respond to smaller doses. Syncope in older patients may be related
to an increased sensitivity and advanced arteriosclerotic vascular disease.
This may be avoided by lower doses. (<linkHtml href="#PRECAUTIONS_Geriatric_Use">See
PRECAUTIONS, Geriatric Use.</linkHtml>)</paragraph>
					</text>
					<effectiveTime value="20060303"/>
				</section>
			</component>
			<component>
				<section>
					<id root="246DA88D-A55E-9EF7-73E8-0398D4DFF89E"/>
					<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
					<title mediaType="text/x-hl7-title+xml">
						<content styleCode="bold">HOW SUPPLIED</content>
					</title>
					<text>
						<paragraph>No. 3294&#160;&#8212; Tablets ALDORIL&#160;15 are salmon,
round, film coated tablets, coded MSD&#160;423 on one side and ALDORIL on
the other. Each tablet contains 250&#160;mg of methyldopa and 15&#160;mg of
hydrochlorothiazide. They are supplied as follows:</paragraph>
						<paragraph>
							<content styleCode="bold">NDC</content> 0006-0423-68 bottles of 100.</paragraph>
						<paragraph>No.
3295&#160;&#8212; Tablets ALDORIL&#160;25 are white, round, film coated tablets,
coded MSD&#160;456 on one side and ALDORIL on the other. Each tablet contains
250&#160;mg of methyldopa and 25&#160;mg of hydrochlorothiazide. They are
supplied as follows:</paragraph>
						<paragraph>
							<content styleCode="bold">NDC</content> 0006-0456-68
bottles of 100</paragraph>
						<paragraph>
							<content styleCode="bold">NDC</content> 0006-0456-82
bottles of 1000.</paragraph>
						<paragraph>No. 3362&#160;&#8212; Tablets ALDORIL&#160;D30
are salmon, oval, film coated tablets, coded MSD&#160;694 on one side and
ALDORIL on the other. Each tablet contains 500&#160;mg of methyldopa and 30&#160;mg
of hydrochlorothiazide. They are supplied as follows:</paragraph>
						<paragraph>
							<content styleCode="bold">NDC</content> 0006-0694-68 bottles of 100.</paragraph>
						<paragraph>No.
3363&#160;&#8212; Tablets ALDORIL&#160;D50 are white, oval, film coated tablets,
coded MSD&#160;935 on one side and ALDORIL on the other. Each tablet contains
500&#160;mg of methyldopa and 50&#160;mg of hydrochlorothiazide. They are
supplied as follows:</paragraph>
						<paragraph>
							<content styleCode="bold">NDC</content> 0006-0935-68
bottles of 100.</paragraph>
					</text>
					<effectiveTime value="20060303"/>
					<component>
						<section>
							<id root="E531AA1C-E19C-4ECD-EA7F-C7E6B18AC808"/>
							<title mediaType="text/x-hl7-title+xml">
								<content styleCode="italics">Storage</content>
							</title>
							<text>
								<paragraph>Keep container tightly closed. Protect from light, moisture,
freezing, &#8211;20&#176;C (&#8211;4&#176;F) and store at controlled room
temperature, 15-30&#176;C (59-86&#176;F).</paragraph>
								<br/>
								<paragraph>MERCK&amp; CO., Inc., Whitehouse Station, NJ 08889, USA</paragraph>
								<paragraph>Issued
February 2004</paragraph>
								<paragraph>Printed in USA</paragraph>
								<br/>
								<paragraph>7843556</paragraph>
							</text>
							<effectiveTime value="20060303"/>
						</section>
					</component>
				</section>
			</component>
		</structuredBody>
	</component>
</document>
